Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News20 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Business22 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News22 hours ago150 jobs in doubt as Bega winds down peanut processing plants in Queensland
-
Business20 hours agoThe best ASX shares to buy and forget for 10+ years